The question of GLP-1 and anesthesia has produced more confusion than almost any other prescribing issue — and much of the advice circulating is out of date. Because these drugs slow gastric emptying, they raise a legitimate concern about aspiration under anesthesia, and early guidance leaned toward simply stopping the drug before surgery. The current, more nuanced guidance says something different: most patients can continue their GLP-1, with a risk-stratified approach for those at higher risk. This guide explains why gastric emptying matters, what the current ASA-endorsed guidance actually recommends, how to counsel and schedule patients, how to coordinate with surgical teams, and when to restart therapy.
It complements our complete prescriber’s guide to GLP-1 medications for weight management and sits alongside the broader safety topics in the library.
The entire perioperative concern flows from one pharmacologic effect: GLP-1 receptor agonists slow gastric emptying (Drucker, 2018). A stomach that empties more slowly may still contain food or fluid even after a standard preoperative fasting period.
Under general anesthesia or deep sedation, protective airway reflexes are blunted, so residual gastric contents raise the theoretical risk of regurgitation and pulmonary aspiration — a rare but serious complication. This is the mechanistic basis, explained further in our GLP-1 mechanism of action explainer, for every perioperative recommendation that follows. The key clinical question is not whether gastric emptying is slowed — it is — but whether routinely stopping the drug actually reduces risk more than it introduces other problems.
Now in the labelingThis is no longer only a society-guidance issue. Since late 2024, the FDA-approved labeling for the GLP-1 class carries a Warnings and Precautions entry on pulmonary aspiration, noting rare postmarketing reports in patients undergoing procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations, and instructing patients to inform their healthcare providers before any planned surgery or procedure (Novo Nordisk, 2025). Documenting that you gave this instruction is now a labeled expectation, not a courtesy.
This is where practice has changed, and where many clinicians are working from outdated information. Early guidance from 2023 leaned toward holding GLP-1s before surgery — day-of dosing for daily agents and roughly a week for weekly agents (American Society of Anesthesiologists, 2023).
The updated multisociety guidance issued in October 2024 took a more individualized, risk-stratified position: most patients can continue their GLP-1 before elective surgery, balancing aspiration risk against the real benefits of continuing therapy for weight and glycemic control (American Society of Anesthesiologists, 2024). For patients at higher risk of retained gastric contents — those on higher doses, in the dose-escalation phase, or with active GI symptoms — the guidance recommends targeted precautions rather than blanket discontinuation: a liquid-only diet for 24 hours before the procedure, deferring elective surgery during active dose escalation, and postponing when a patient has ongoing nausea, vomiting, or abdominal symptoms. Conditions that independently slow gastric motility, such as Parkinson’s disease, push a patient into the same higher-risk group. Point-of-care gastric ultrasound can be used just before the procedure to assess stomach contents in the highest-risk patients. Notably, the guidance cautions against withholding these drugs from patients simply because they are obese, which could reflect bias rather than clinical judgment.
In practice, the guidance sorts patients into three broad tiers. Most fall into the first.
| Risk tier | Typical patient | Pre-procedure plan |
|---|---|---|
| Lower risk | Stable on a maintenance dose, no GI symptoms, routine elective procedure | Continue the GLP-1; standard fasting per the facility’s protocol |
| Higher risk | On a higher dose, actively escalating (typically the first 4–8 weeks), or a condition that slows motility | Liquid-only diet for 24 hours beforehand; where feasible, defer elective surgery until escalation is complete |
| Highest risk | Ongoing nausea, vomiting, abdominal pain, or constipation | Postpone elective procedures until symptoms resolve; if proceeding, point-of-care gastric ultrasound immediately before |
Active GI symptoms are the single clearest signal to pause, which is one more reason that managing GI side effects proactively has downstream value: a patient whose nausea is controlled is a patient whose elective surgery does not get cancelled the morning of.
The reversal was not a softening of standards; it followed the evidence. Two findings sit side by side and both are true.
First, GLP-1 users really do have more in their stomachs. In a 316-patient study using preoperative gastric ultrasound, 35.8% of fasted patients on a GLP-1 had high residual gastric content, and the factors associated with that finding included fasting from solids for 21.3 hours or less and withholding the injection for 7.5 days or less (Pai et al., 2026). Pooled analyses have put the odds of residual gastric content at roughly six times that of non-users. That is a real, measurable effect — and it is also why a short hold is not the reassurance clinicians once assumed it was.
Second, that residual content has not translated into more aspiration. A systematic review of seven retrospective cohorts covering 541,408 patients found no statistically significant increase in aspiration risk for GLP-1 users, with a pooled relative risk of 1.00 for elective surgery and 1.10 for endoscopy. For scale, the same analysis found opioid users carried a relative risk of 2.68 — a genuine signal the method was clearly capable of detecting (Ho et al., 2025). Holding the drug, meanwhile, sacrifices glycemic and weight control and does not reliably empty the stomach. That asymmetry — measurable stomach contents, unmeasurable increase in harm, real cost to stopping — is the whole argument for risk stratification over blanket discontinuation.
Translating the guidance into practice starts with counseling. Every patient on a GLP-1 should understand that they must tell any surgeon, proceduralist, or anesthesiologist that they take one — this single disclosure drives the entire perioperative plan, and patients often do not think to mention a weight-loss medication. The most reliable way to make that happen is to say it at the same visit you say everything else: the perioperative instruction belongs in the same counseling block as your contraindication screening and patient selection conversation, not as an afterthought months later.
Scheduling matters too. Where feasible, elective procedures are best planned outside the active dose-escalation window, when gastric-emptying effects and GI symptoms are most pronounced. A patient who is stable on a maintenance dose and free of GI symptoms is generally in a better position than one mid-titration. When a liquid-diet or fasting adjustment is indicated for a higher-risk patient, give clear, written instructions well in advance rather than the day before.
Perioperative GLP-1 management is a shared decision, not a unilateral one. The prescriber’s role is to communicate proactively: confirm the specific agent, dose, and where the patient is in their titration, and flag any active GI symptoms. The anesthesia team ultimately owns the airway-risk assessment and any decision to proceed, delay, or use additional precautions such as gastric ultrasound or a modified anesthetic approach.
Because institutional protocols vary, the safest posture is to defer to the operating facility’s and anesthesiologist’s current policy while supplying them with complete, accurate medication information (Novo Nordisk, 2025). Documenting that communication — what was disclosed, what was decided, and by whom — protects the patient and every clinician involved. Building these perioperative habits into a repeatable protocol is part of what structured programs such as IAPAM’s CME-accredited GLP-1 training are designed to instill.
Some facilities still run the 2023 hold protocol, and a few now ask prescribers to sign off on continuing the drug. Neither is a fight worth having in the pre-op bay. Keep a one-page summary of the current multisociety guidance, the patient’s agent, dose, weeks-on-dose, and symptom status, and send it with the clearance note. Giving the anesthesia team the facts they need to stratify is more persuasive — and faster — than debating the policy.
Resuming a GLP-1 after a procedure is usually straightforward but should be deliberate. In general, therapy can restart once the patient is tolerating their normal oral intake and has no significant postoperative GI issues, following the facility’s guidance for the specific procedure.
Two practical points matter. If the medication was held for an extended period around a complex procedure, tolerability at the prior dose may no longer hold, and re-titrating from a lower dose can be the more comfortable path — the step-down and step-up rules differ by agent, so work from the semaglutide titration schedule or the tirzepatide dosing guide rather than from memory. And postoperative factors — nausea, reduced intake, other new medications — should be accounted for before resuming. When in doubt, coordinate the restart with the surgical team rather than resuming automatically.
Semaglutide and tirzepatide changed what patients expect from their providers. IAPAM’s GLP-1 certification gives you the protocols, titration schedules, monitoring parameters and side-effect management to run a medically supervised weight management program with confidence.
What the certification covers
For MD/DO, NP, APRN, PA, RN and other licensed providers
GLP-1 Essentials for Weight Loss — self-paced
3 CMEs · 3-5 hours · 24/7 access
Certified Medical Weight Management Provider™ (CWMP)
6 CMEs · 8-10 hours · 24/7 access
Questions? Call 1-866-211-6901
Not routinely, under current guidance. The 2024 multisociety guidance recommends that most patients continue their GLP-1 before elective surgery, with targeted precautions — such as a 24-hour liquid diet or deferring during dose escalation — for those at higher risk of retained gastric contents.
They slow gastric emptying, so the stomach may still contain contents after standard fasting. Under anesthesia, when protective airway reflexes are reduced, this raises the theoretical risk of regurgitation and aspiration.
Current guidance suggests a liquid-only diet for 24 hours beforehand for those on higher doses, deferring elective surgery during active dose escalation, postponing if GI symptoms are present, and considering gastric ultrasound just before the procedure to assess stomach contents.
No. In a 316-patient gastric ultrasound study, 35.8% of fasted patients on a GLP-1 still had high residual gastric contents, and holding the injection for 7.5 days or less was one of the factors associated with that finding. A short hold is not a substitute for individualized assessment, which is part of why blanket discontinuation fell out of favor.
Always. Disclosure is the single most important step, because it lets the anesthesia team assess aspiration risk and choose appropriate precautions. GLP-1 labeling now instructs patients to inform their healthcare providers before any planned surgery or procedure, so make this a standing counseling point at every visit.
Generally once the patient is tolerating normal oral intake without significant postoperative GI issues, following the facility’s guidance. If the drug was held for an extended period, re-titrating from a lower dose may be more comfortable.
No. Current guidance specifically cautions against withholding these medications from patients simply because they are obese, as that can reflect bias rather than an individualized clinical assessment.
Perioperative GLP-1 management has shifted from “stop the drug” to “assess the risk.” Under current guidance, most patients can continue their GLP-1 before elective surgery, with a liquid diet, scheduling adjustments, or gastric ultrasound reserved for those at higher risk. The prescriber’s job is to counsel patients to disclose the medication, coordinate proactively with surgical and anesthesia teams, and restart therapy thoughtfully.
For the full clinical workflow, see our complete prescriber’s guide to GLP-1 medications. And to keep your perioperative and safety protocols current, IAPAM’s GLP-1 clinical training and certification — backed by more than 20 years of training healthcare professionals and over 6,300 five-star reviews — gives you evidence-based clinical frameworks. Clinicians expanding a cash-pay practice often add aesthetic services alongside weight management; the same foundation supports Botox® training for nurse practitioners.
Explore GLP-1 Certification Training →
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Perioperative guidance evolves; always follow the most current society recommendations and coordinate decisions with the patient’s surgical and anesthesia teams.
IAPAM Learning Lab
Patients are already asking about GLP-1s, injectables, PRP, lasers, and aesthetic treatments. Build the knowledge to have better clinical conversations now—on a schedule that works around your practice.
Need hands-on BOTOX® training instead? Explore IAPAM’s Botox training options →
Medical Weight Management Training
Build the clinical, operational, and business foundations to evaluate GLP-1 weight-management services for your practice—without handing your patient relationships to a corporate intermediary.
Explore GLP-1 Certification Training →Want to add Botox® training to your broader practice plan? Explore IAPAM’s Botox training options →
In order to have a successful aesthetic practice, you need to have effective advertising to attract people to your business.
This includes spending those
While Ozempic® has been proven effective in clinical trials, a potential reason for not losing weight on Ozempic® is related to dietary and lifestyle choices.
Failure to refrigerate the Ozempic® within the correct temperature range may result in reduced effectiveness and potential harm to the user.
Learn about the effects of stopping Ozempic® for diabetes & weight loss. Manage withdrawal & maintain health gains.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.
Terms and conditions apply. Offer expires October 31.